RESMED INC
RMDNYSE · SIC 3841
$198.99
↓ -1.9%Jul 17 close · end-of-day
Price
1Y↓ -21.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$29.0B
Enterprise Value
$28.0B
P/E
19.2
P/S
5.2
P/B
4.5
EV/EBITDA
13.3
PEG
0.9
FCF Yield
6.0%
Dividend Yield
1.2%
Revenue (TTM)
$5.5B
Net Income (TTM)
$1.5B
Free Cash Flow (TTM)
$1.8B
Gross Margin
61.6%
Operating Margin
34.2%
Net Margin
27.4%
ROE
23.4%
ROIC
27.5%
Debt / Equity
0.1
Net Cash
$996.4M
Return 1Y
-21.6%
Company profile
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company also provides AirView, a system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools.
- CEO
- Michael J. Farrell
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 8,160
- Headquarters
- California
- Website
- resmed.com
Management & directors
- Farrell Michael J.Chief Executive Officer
- Rider Michael JGlobal General Counsel
- Sandercock BrettChief Financial Officer
- Leong JustinChief Product Officer
Roles derived from SEC Form 4 filings.
Earnings
Next earnings · estimated2026-10-06
RMD Q3 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$1.4B↑ +10.8%
Diluted EPS$2.74↑ +10.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $3.2B | $3.6B | $4.2B | $4.7B | $5.1B |
| Gross profit | $1.8B | $2.0B | $2.4B | $2.7B | $3.1B |
| Operating income | $903.7M | $1.0B | $1.1B | $1.3B | $1.7B |
| Net income | $474.5M | $779.4M | $897.6M | $1.0B | $1.4B |
| Diluted EPS | $3.24 | $5.30 | $6.09 | $6.92 | $9.51 |
| Operating cash flow | $736.7M | $351.1M | $693.3M | $1.4B | $1.8B |
| Free cash flow | $634.0M | $216.3M | $573.6M | $1.3B | $1.7B |
| Gross margin | 57.5% | 56.6% | 55.8% | 56.7% | 59.4% |
| Operating margin | 28.3% | 28.0% | 26.8% | 28.2% | 32.7% |
| Net margin | 14.8% | 21.8% | 21.3% | 21.8% | 27.2% |
| Line item | Q4 '24 | Q1 '24 | Q2 '24 | Q3 '25 | Q4 '25 | Q1 '25 | Q2 '25 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2B | $1.2B | $1.3B | $1.3B | $1.3B | $1.3B | $1.4B | $1.4B |
| Gross profit | $715.5M | $717.2M | $751.3M | $766.4M | $820.1M | $820.8M | $878.7M | $891.0M |
| Operating income | $381.2M | $387.3M | $417.2M | $426.3M | $454.5M | $446.5M | $491.7M | $499.8M |
| Net income | $292.2M | $311.4M | $344.6M | $365.0M | $379.7M | $348.5M | $392.6M | $398.7M |
| Diluted EPS | $1.97 | $2.11 | $2.34 | $2.48 | $2.58 | $2.37 | $2.68 | $2.74 |
| Operating cash flow | $440.1M | $325.5M | $308.6M | $578.7M | $538.8M | $457.3M | $339.7M | $554.1M |
| Free cash flow | $415.2M | $307.7M | $288.0M | $557.9M | $508.2M | $414.4M | $311.2M | $520.5M |
| Gross margin | 58.5% | 58.6% | 58.6% | 59.3% | 60.8% | 61.5% | 61.8% | 62.2% |
| Operating margin | 31.2% | 31.6% | 32.5% | 33.0% | 33.7% | 33.4% | 34.6% | 34.9% |
| Net margin | 23.9% | 25.4% | 26.9% | 28.3% | 28.2% | 26.1% | 27.6% | 27.9% |
Company news
Jul 16, 2026
Jul 10, 2026
Jul 9, 2026
Jul 8, 2026
- 12d agoResmed sharpens sleep care focus with $490m software business salemedicaldevice-network.com
- 12d agoDow Jones and Nasdaq start lower as Trump says Iran ceasefire 'over'proactiveinvestors.com
- 12d agoHere is why Taiwan Semiconductor (TSM) Is Among the Best Stocks in Glen Kacher’s Portfoliofinance.yahoo.com
- 12d agoResmed to sell MatrixCare for $490M to private equity firmmedtechdive.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-07 | Farrell Michael J.· Chairman and CEO | Sale | 4,991 | $218.55 | $1.1M | filing |
| 2026-07-07 | Farrell Michael J.· Chairman and CEO | Option exercise | 4,991 | $146.34 | $730,382.94 | filing |
| 2026-06-08 | Farrell Michael J.· Chairman and CEO | Sale | 4,991 | $193.96 | $968,064.34 | filing |
| 2026-06-08 | Farrell Michael J.· Chairman and CEO | Option exercise | 4,991 | $146.34 | $730,382.94 | filing |
| 2026-06-01 | Rider Michael J· Global General Counsel | Tax withholding | 269 | $190.57 | $51,214.16 | filing |
| 2026-05-07 | Farrell Michael J.· Chairman and CEO | Sale | 4,991 | $207.82 | $1.0M | filing |
| 2026-05-07 | Farrell Michael J.· Chairman and CEO | Option exercise | 4,991 | $146.34 | $730,382.94 | filing |
| 2026-04-07 | Farrell Michael J.· Chairman and CEO | Sale | 4,991 | $225.50 | $1.1M | filing |
| 2026-04-07 | Farrell Michael J.· Chairman and CEO | Option exercise | 4,991 | $146.34 | $730,382.94 | filing |
| 2026-04-01 | FARRELL PETER C | Sale | 2,000 | $225.00 | $450,000.00 | filing |
| 2026-04-01 | Sandercock Brett· Chief Financial Officer | Sale | 1,000 | $224.31 | $224,310.00 | filing |
| 2026-03-09 | Farrell Michael J.· Chairman and CEO | Sale | 4,991 | $251.03 | $1.3M | filing |
| 2026-03-09 | Farrell Michael J.· Chairman and CEO | Option exercise | 4,991 | $146.34 | $730,382.94 | filing |
| 2026-03-04 | FARRELL PETER C | Sale | 2,000 | $260.22 | $520,440.00 | filing |
| 2026-03-02 | Sandercock Brett· Chief Financial Officer | Sale | 1,000 | $254.30 | $254,300.00 | filing |
| 2026-02-09 | Farrell Michael J.· Chairman and CEO | Sale | 4,991 | $273.78 | $1.4M | filing |
| 2026-02-09 | Farrell Michael J.· Chairman and CEO | Option exercise | 4,991 | $146.34 | $730,382.94 | filing |
| 2026-02-04 | FARRELL PETER C | Sale | 2,000 | $251.31 | $502,620.00 | filing |
| 2026-02-04 | Rider Michael J· Global General Counsel | Sale | 50 | $260.00 | $13,000.00 | filing |
| 2026-02-02 | Sandercock Brett· Chief Financial Officer | Sale | 1,000 | $257.03 | $257,030.00 | filing |
| 2026-01-07 | Farrell Michael J.· Chairman and CEO | Sale | 4,991 | $248.46 | $1.2M | filing |
| 2026-01-07 | Farrell Michael J.· Chairman and CEO | Option exercise | 4,991 | $146.34 | $730,382.94 | filing |
| 2026-01-07 | FARRELL PETER C | Sale | 2,000 | $248.83 | $497,660.00 | filing |
| 2026-01-02 | Sandercock Brett· Chief Financial Officer | Sale | 1,000 | $241.75 | $241,750.00 | filing |
| 2026-01-02 | Rider Michael J· Global General Counsel | Sale | 50 | $241.75 | $12,087.50 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.